MUC-1 vaccine; tecemotide; liposomal BLP25; Stimuvax
Jump to navigation
Jump to search
Indications
- in conjunction with standard neoadjuvant systemic therapy improves distant relapse-free survival & overall survival rates in breast cancer patients
Mechanism of action
- inhibits expression of MUC-1 glycoprotein
- overexpressed in > 90% of breast cancers
- resistant to cancer chemotherapy
More general terms
References
- ↑ McKnight W MUC-1 vaccine associated with notable overall survival rates in breast cancer. MDedge. June 27, 2024 https://ma1.mdedge.com/hematology-oncology/article/269760/breast-cancer/muc-1-vaccine-associated-notable-overall-survival